223 related articles for article (PubMed ID: 14555987)
1. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
Simeone AM; Broemeling LD; Rosenblum J; Tari AM
Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
[TBL] [Abstract][Full Text] [Related]
2. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide.
Simeone AM; Ekmekcioglu S; Broemeling LD; Grimm EA; Tari AM
Mol Cancer Ther; 2002 Oct; 1(12):1009-17. PubMed ID: 12481423
[TBL] [Abstract][Full Text] [Related]
3. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
Simeone AM; Deng CX; Kelloff GJ; Steele VE; Johnson MM; Tari AM
Carcinogenesis; 2005 May; 26(5):1000-7. PubMed ID: 15695235
[TBL] [Abstract][Full Text] [Related]
4. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
Simeone AM; Colella S; Krahe R; Johnson MM; Mora E; Tari AM
Carcinogenesis; 2006 Mar; 27(3):568-77. PubMed ID: 16199439
[TBL] [Abstract][Full Text] [Related]
5. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.
Simeone AM; Li YJ; Broemeling LD; Johnson MM; Tuna M; Tari AM
Cancer Res; 2004 Feb; 64(4):1224-8. PubMed ID: 14973114
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
Tuna M; Chavez-Reyes A; Tari AM
Oncogene; 2005 Feb; 24(9):1648-52. PubMed ID: 15674342
[TBL] [Abstract][Full Text] [Related]
12. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
13. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
Shiu LY; Liang CH; Chang LC; Sheu HM; Tsai EM; Kuo KW
Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.
Koay DC; Zerillo C; Narayan M; Harris LN; DiGiovanna MP
Breast Cancer Res; 2010; 12(4):R62. PubMed ID: 20696059
[TBL] [Abstract][Full Text] [Related]
16. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells.
Siwak DR; Mendoza-Gamboa E; Tari AM
Int J Oncol; 2003 Dec; 23(6):1739-45. PubMed ID: 14612949
[TBL] [Abstract][Full Text] [Related]
18. N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells.
Lim SJ; GutiƩrrez-Puente Y; Tari AM
Tumour Biol; 2002; 23(5):279-86. PubMed ID: 12595744
[TBL] [Abstract][Full Text] [Related]
19. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
20. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]